Long-acting Beta-agonists Market Segmentation:
Route of Administration Segment Analysis
Inhalation segment in the long-acting beta-agonists market is anticipated to garner the largest share of 92.4% by the end of 2035. The segment’s upliftment is highly attributed to the aspect of delivering LABAs directly to the lungs, thereby ensuring an increase in the onset of action at a low dosage, while reducing systemic side effects. This is considered a targeted approach, which is the international treatment for administering obstructive airway diseases, such as COPD and asthma. The segment’s growth is further propelled by ongoing advancements in inhaler device technology, which boosts patient adherence and drug delivery efficacy, thus denoting an optimistic outlook for the segment.
Drug Type Segment Analysis
Combination therapies (LABA/ICS) segment in the market is projected to cater to the second-largest share during the forecast duration. The segment’s growth is highly fueled by its clinical advantage to successfully aid patients with mild, moderate, and critical persistent asthma. According to an article published by Heliyon in June 2024, a clinical study was conducted on 78,171 patients, wherein the ICS/LABA treatment as a single relief and maintenance therapy has been proven to be suitable to diminish the future risk of severe asthma by an estimated 60%, thereby suitable for the segment’s exposure.
Application Segment Analysis
Chronic obstructive pulmonary disease (COPD) segment in the long-acting beta-agonists (LABA) market is expected to constitute the third-largest share by the end of the projected timeline. The segment’s development is highly driven by the provision of long-term bronchodilation, enhancing lung function, diminishing breathlessness, and boosting the overall quality of life. As per an article published by the GOLD COPD Organization in November 2024, ICS treatment is combined with LABA for more than 2 exacerbations of COPD every year, followed by blood eosinophils of over 300 cells, and a record of concomitant asthma.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Route of Administration |
|
|
Drug Type |
|
|
Application |
|
|
Distribution Channel |
|
|
Product Type |
|
|
End user |
|
